214 related articles for article (PubMed ID: 22113619)
1. 18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation.
Derlin T; Weber C; Habermann CR; Herrmann J; Wisotzki C; Ayuk F; Wolschke C; Klutmann S; Kröger N
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):493-500. PubMed ID: 22113619
[TBL] [Abstract][Full Text] [Related]
2. Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation.
Derlin T; Peldschus K; Münster S; Bannas P; Herrmann J; Stübig T; Habermann CR; Adam G; Kröger N; Weber C
Eur Radiol; 2013 Feb; 23(2):570-8. PubMed ID: 22843058
[TBL] [Abstract][Full Text] [Related]
3. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
[TBL] [Abstract][Full Text] [Related]
4. Treatment response evaluation with
Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
[TBL] [Abstract][Full Text] [Related]
5. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.
Dammacco F; Rubini G; Ferrari C; Vacca A; Racanelli V
Clin Exp Med; 2015 Feb; 15(1):1-18. PubMed ID: 25218739
[TBL] [Abstract][Full Text] [Related]
6. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of [
Stolzenburg A; Lückerath K; Samnick S; Speer M; Kneer K; Schmid JS; Grigoleit GU; Hofmann S; Beer AJ; Bunjes D; Knop S; Buck AK; Einsele H; Lapa C
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1694-1704. PubMed ID: 29610955
[TBL] [Abstract][Full Text] [Related]
8. PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: comparison of distribution patterns and tracers' pharmacokinetics.
Sachpekidis C; Goldschmidt H; Hose D; Pan L; Cheng C; Kopka K; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1343-53. PubMed ID: 24562650
[TBL] [Abstract][Full Text] [Related]
9. Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome.
Tirumani SH; Sakellis C; Jacene H; Shinagare AB; Munshi NC; Ramaiya NH; Van den Abbeele AD
Clin Nucl Med; 2016 Jan; 41(1):e7-13. PubMed ID: 26252323
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study.
Fonti R; Pace L; Cerchione C; Catalano L; Salvatore B; De Luca S; Pane F; Salvatore M; Del Vecchio S
Clin Nucl Med; 2015 Apr; 40(4):303-8. PubMed ID: 25608167
[TBL] [Abstract][Full Text] [Related]
11. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M
Haematologica; 2007 Jan; 92(1):50-5. PubMed ID: 17229635
[TBL] [Abstract][Full Text] [Related]
12. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).
Nanni C; Zamagni E; Versari A; Chauvie S; Bianchi A; Rensi M; Bellò M; Rambaldi I; Gallamini A; Patriarca F; Gay F; Gamberi B; Cavo M; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):414-21. PubMed ID: 26475305
[TBL] [Abstract][Full Text] [Related]
13. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma.
Fonti R; Larobina M; Del Vecchio S; De Luca S; Fabbricini R; Catalano L; Pane F; Salvatore M; Pace L
J Nucl Med; 2012 Dec; 53(12):1829-35. PubMed ID: 23071351
[TBL] [Abstract][Full Text] [Related]
14. Is there any complimentary role of F-18 NaF PET/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET/CT and F-18 FDG NaF PET/CT.
Ak İ; Onner H; Akay OM
Ann Hematol; 2015 Sep; 94(9):1567-75. PubMed ID: 26068066
[TBL] [Abstract][Full Text] [Related]
15. The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients.
Nanni C; Zamagni E; Celli M; Caroli P; Ambrosini V; Tacchetti P; Brioli A; Zannetti B; Pezzi A; Pantani L; Perrone G; Zompatori M; Cavo M; Colletti PM; Rubello D; Fanti S
Clin Nucl Med; 2013 Feb; 38(2):e74-9. PubMed ID: 23143049
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
[TBL] [Abstract][Full Text] [Related]
17. 18 FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation.
Lapa C; Lückerath K; Malzahn U; Samnick S; Einsele H; Buck AK; Herrmann K; Knop S
Oncotarget; 2014 Sep; 5(17):7381-91. PubMed ID: 25277179
[TBL] [Abstract][Full Text] [Related]
18. Comparison of (11)C-4'-thiothymidine, (11)C-methionine, and (18)F-FDG PET/CT for the detection of active lesions of multiple myeloma.
Okasaki M; Kubota K; Minamimoto R; Miyata Y; Morooka M; Ito K; Ishiwata K; Toyohara J; Inoue T; Hirai R; Hagiwara S; Miwa A
Ann Nucl Med; 2015 Apr; 29(3):224-32. PubMed ID: 25421383
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma.
Westerland O; Amlani A; Kelly-Morland C; Fraczek M; Bailey K; Gleeson M; El-Najjar I; Streetly M; Bassett P; Cook GJR; Goh V;
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2558-2565. PubMed ID: 33469686
[TBL] [Abstract][Full Text] [Related]
20. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
Li DL; Xu YK; Wang QS; Wu HB; Li HS
Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
